melanotan-2 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-22. Anything still debated is marked as such rather than presented as settled.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Melanotan II; MT-II; N-acetyl-norleucyl-cyclo[Asp-His-D-Phe-Arg-Trp-Lys] amide | Naming follows peptide convention; the numeral distinguishes it from melanotan-1 |
| Molecular formula | C50H69N15O9 | Includes the lactam bridge; no counter-ion assumed |
| Monoisotopic mass | 1023.53 Da | Free base; salts and counter-ions shift the observed value |
| Appearance | White to off-white lyophilised powder | Batch-to-batch colour variation is not itself proof of impurity |
| Typical analytical method | RP-HPLC purity determination with ESI-MS identity confirmation | Retention time alone does not establish sequence identity |
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
=== Copper toxicity from excess exposures === In humans, the liver is the primary organ of copper-induced toxicity. Other target organs include bone and the central nervous and immune systems. Excess copper intake also induces toxicity indirectly by interacting with other nutrients. For example, excess copper intake produces anemia by interfering with iron transport and/or metabolism. The identification of genetic disorders of copper metabolism leading to severe copper toxicity (i.e., Wilson disease) has spurred research into the molecular genetics and biology of copper homeostasis (for further information, refer to the following section on copper genetic diseases). Much attention has focused on the potential consequences of copper toxicity in normal and potentially susceptible populations. Potentially susceptible subpopulations include hemodialysis patients and individuals with chronic liver disease. Recently, concern was expressed about the potential sensitivity to liver disease of individuals who are heterozygote carriers of Wilson disease genetic defects (i.e., those having one normal and one mutated Wilson copper ATPase gene) but who do not have the disease (which requires defects in both relevant genes). However, to date, no data are available that either support or refute this hypothesis.
== Capacity == The warehouse has an area of 505,139 square feet (46,928.9 m2)—of which 456,412 square feet (42,402.1 m2) is refrigerated—and a volume of 36,340,650 cubic feet (1,029,053 m3). The facility is capable of storing about 350 million pounds (160 kt) of frozen food. 2800 Polar Way is the largest refrigerated building on earth by usable volume. In 2019, the company purchased an additional 8.6-acre (3.5 ha) lot to expand facilities by one third.
This method can be set up in various configurations. In its simplest form, a nutrient-and-water solution is manually applied one or more times per day to a container of inert growing media, such as rockwool, perlite, vermiculite, coco fibre, or sand. In a slightly more complex system, it is automated with a delivery pump, a timer and irrigation tubing to deliver nutrient solution with a delivery frequency that is governed by the key parameters of plant size, plant growing stage, climate, substrate, and substrate conductivity, pH, and water content. In a commercial setting, watering frequency is multi-factorial and governed by computers or PLCs. Commercial hydroponics production of large plants like tomatoes, cucumber, and peppers uses one form or another of run-to-waste hydroponics.
== Labeling == The actual leather content of bonded leather varies depending on the manufacturer and the quality level. There is some debate and controversy over the ethics of using the term "bonded leather" to describe an upholstery product, which is actually a reconstituted leather, specifically in the home furnishings industry. A Leather Research Laboratory commented calling a product "bonded leather" is "deceptive because it does not represent its true nature. It's a vinyl, or a polyurethane laminate or a composite, but it's not leather". In 2011 the European Committee for Standardization published EN 15987:2011 'Leather - Terminology - Key definitions for the leather trade' to stop confusion about bonded leather, according to which the minimum amount of 50% in weight of dry leather is needed to use the term "bonded leather". The US Federal Trade Commission recommends giving a percentage of leather included. The Federal Trade Commission has said that "The guidelines caution against misrepresentations about the leather content in products containing ground, reconstituted, or bonded leather, and state that such products, when they appear to be made of leather, should be accompanied by a disclosure as to the percentage of leather or other fiber content. The guidelines also state that these disclosures should be included in any product advertising that might otherwise mislead consumers as to the composition of the product."
==== MeSH D12.776.467.374.400 – growth substances ==== MeSH D12.776.467.374.400.442 – hematopoietic cell growth factors MeSH D12.776.467.374.400.442.240 – colony-stimulating factors MeSH D12.776.467.374.400.442.240.075 – colony-stimulating factors, recombinant MeSH D12.776.467.374.400.442.240.075.350 – granulocyte colony stimulating factor, recombinant MeSH D12.776.467.374.400.442.240.075.350.275 – filgrastim MeSH D12.776.467.374.400.442.240.075.375 – granulocyte macrophage colony-stimulating factors, recombinant MeSH D12.776.467.374.400.442.240.150 – erythropoietin MeSH D12.776.467.374.400.442.240.150.250 – erythropoietin, recombinant MeSH D12.776.467.374.400.442.240.150.250.250 – epoetin alfa MeSH D12.776.467.374.400.442.240.350 – granulocyte colony-stimulating factor MeSH D12.776.467.374.400.442.240.350.375 – granulocyte colony stimulating factor, recombinant MeSH D12.776.467.374.400.442.240.350.375.275 – filgrastim MeSH D12.776.467.374.400.442.240.375 – granulocyte-macrophage colony-stimulating factor MeSH D12.776.467.374.400.442.240.375.275 – granulocyte macrophage colony-stimulating factors, recombinant MeSH D12.776.467.374.400.442.240.400 – interleukin-3 MeSH D12.776.467.374.400.442.240.500 – macrophage colony-stimulating factor MeSH D12.776.467.374.400.442.240.750 – thrombopoietin MeSH D12.776.467.374.400.442.800 – stem cell factor MeSH D12.776.467.374.400.505 – interleukins MeSH D12.776.467.374.400.505.501 – interleukin-1 MeSH D12.776.467.374.400.505.502 – interleukin-2 MeSH D12.776.467.374.400.505.503 – interleukin-3 MeSH D12.776.467.374.400.505.504 – interleukin-4 MeSH D12.776.467.374.400.505.505 – interleukin-5 MeSH D12.776.467.374.400.505.506 – interleukin-6 MeSH D12.776.467.374.400.505.507 – interleukin-7 MeSH D12.776.467.374.400.505.508 – interleukin-8 MeSH D12.776.467.374.400.505.509 – interleukin-9 MeSH D12.776.467.374.400.505.510 – interleukin-10 MeSH D12.776.467.374.400.505.511 – interleukin-11 MeSH D12.776.467.374.400.505.512 – interleukin-12 MeSH D12.776.467.374.400.505.513 – interleukin-13 MeSH D12.776.467.374.400.505.514 – interleukin-14 MeSH D12.776.467.374.400.505.515 – interleukin-15 MeSH D12.776.467.374.400.505.516 – interleukin-16 MeSH D12.776.467.374.400.505.517 – interleukin-17 MeSH D12.776.467.374.400.505.518 – interleukin-18 MeSH D12.776.467.374.400.800 – transforming growth factor beta
Sources: en.wikipedia.org
LSD was initially explored for psychiatric use due to its structural similarity to the neurotransmitter serotonin and its safety profile. In the 1950s and 1960s, it was used in psychiatry to enhance psychotherapy, known as psychedelic therapy. In the United States, the earliest research began in the 1950s. Albert Kurland and his colleagues published research on LSD's therapeutic potential to treat schizophrenia. In Canada, Humphry Osmond and Abram Hoffer completed LSD studies as early as 1952. Some psychiatrists, such as Ronald A. Sandison, who pioneered its use at Powick Hospital in England, believed that LSD was especially useful at helping patients to "unblock" repressed subconscious material through other psychotherapeutic methods, and also for treating alcoholism. One study concluded, "The root of the therapeutic value of the LSD experience is its potential for producing self-acceptance and self-surrender," presumably by forcing the user to face issues and problems in that individual's psyche. By the 1960s, however, controversies surrounding "hippie" counterculture began to deplete institutional support for continued study. In 2001, the United States Drug Enforcement Administration (DEA) stated that LSD "produces no aphrodisiac effects, does not increase creativity, has no lasting positive effect in treating alcoholics or criminals, does not produce a "model psychosis", and does not generate immediate personality change." In more recent years, there has been renewed clinical research on and interest in LSD for potential therapeutic uses.
The strength and direction of these fields are the same regardless of the size of a wound. Healing of skin wounds is a complex process involving the cooperation of various elements of the body, such as platelets, immune cells, epithelial cells, and fibroblasts. This process is coordinated largely by chemical signals, but there is evidence that electrotaxis plays an additional role in directing specific cell types toward the site of an injury. During the proliferation phase of recovery, keratinocytes move toward the cathodal side of the EFs occurring around and injury, bringing them toward the edge of the wound. In fact, in vitro experimentation found that application of physiological strength EFs could override other signals and guide cells to migrate towards or even away from a wound depending on the direction of the field, regardless of chemical factors. EFs have also experimentally been found to influence cell migration in human umbilical vein cells, dermal fibroblasts, and myofibroblasts.
=== Tahini's === Tahini's is a fast-casual Mediterranean and Middle Eastern fusion restaurant chain founded in London, Ontario, in 2012 by Omar Hamam. The chain is known for blending traditional shawarma with international cuisine, featuring items such as butter chicken shawarma, Jamaican jerk shawarma, and shawarma ramen. As of 2026, Tahini's operates over 70 locations across Canada and has begun expanding into international markets including the United States.
The oil-drug emulsion must have low solubility with the polymer membrane to ensure that the drug will be carried throughout the system properly and be released at the proper time and location. When the proper emulsion is obtained, the drug should be uniformly dispersed throughout the entire internal cavity of the polymeric membrane.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.
The natural hormone is a linear tridecapeptide that is rapidly degraded in circulation. Melanotan-2 is shortened, cyclised, N-terminally acetylated, and carries a D-amino acid substitution, all of which slow enzymatic breakdown.
No national medicines regulator has approved melanotan-2 for therapeutic or cosmetic use. In several jurisdictions it is treated as an unapproved prescription medicine, and its legal classification differs from country to country.
Low temperature slows hydrolysis and oxidation, the two main routes by which the peptide backbone and side chains are modified. A lyophilised powder stored at −20 °C is more stable than one kept at room temperature, and once the material is dissolved the degradation rate rises, making refrigeration more important.